Discovery And Optimization Of Potent Gpr40 Full Agonists Containing Tricyclic Spirocycles
Yingcai Wang,Jiwen Liu,Paul J. Dransfield,Liusheng Zhu,Zhongyu Wang,Xianyun Jiao,Yongli Su,An-Rong Li,Annie Kasparian,Sean P. Brown,Marc Vimolratana,Xiaohui Du,Ming Yu,Vatee Pattaropong,Jonathan B. Houze,Gayathri Swaminath,Thanhvien Tran,Khanh Nguyen,Qi Guo,Jane Zhang,Run Zhuang,Frank Li,Lynn Miao,Michael D. Bartberger,Tiffany L. Correll,David Chow,Simon Wong,Jian Luo,Daniel Lin,Julio C. Medina
DOI: https://doi.org/10.1021/ml300427u
2013-01-01
ACS Medicinal Chemistry Letters
Abstract:GPR40 (FFAR1 or FFA1) is a target of high interest being pursued to treat type II diabetes due to its unique mechanism leading to little risk of hypoglycemia. We recently reported the discovery of AM-1638 (2), a potent full agonist of GPR40. In this report, we present the discovery of GPR40 full agonists containing conformationally constrained tricyclic spirocycles and their structure-activity relationships leading to more potent agonists such as AM-5262 (26) with improved rat PK profile and general selectivity profile. AM-5262 enhanced glucose stimulated insulin secretion (mouse and human islets) and improved glucose homeostasis in vivo (OGTT in HF/STZ mice) when compared to AM-1638.